ClinicalTrials.gg
CompletedNCT07025551Updated Feb 27, 2026

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

A Phase 1 interventional study of MK-8527 in Hepatic Impairment and Healthy Participants, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to learn what happens to MK-8527 in a person's body over time (a pharmacokinetic [PK] study). Researchers will compare what happens to MK-8527 in the body when it is given to healthy participants and participants with mild and moderate hepatic (liver) impairment.

02

Conditions studied

  • Hepatic Impairment
  • Healthy Participants
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

All participants:

  • Is a continuous non-smoker or moderate smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to dosing
  • Has (BMI) ≥ 18.0 and ≤ 40.0 kg/m\^2

Participants with Mild HI (Group 1) and Moderate HI (Group 2):

  • Has mild or moderate hepatic impairment
  • Has a diagnosis of chronic, stable, hepatic insufficiency with features of cirrhosis due to any etiology
  • Is generally in good health with the exception of HI

Healthy Control Participants (Group 3):

- Healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

All participants:

  • Has a history of cancer ()
  • Has positive results for (HIV)
  • Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing

Participants with Mild HI (Group 1) and Moderate HI (Group 2):

  • With the exception of HI, has a history or presence of medical or psychiatric condition or disease
  • Is positive for surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb)
  • Is positive for Virus (HCV)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Mild Hepatic Impairment (Group 1)

    All participants will receive a single dose of MK-8527 on Day 1.

    Drug: MK-8527

  • Experimental
    Moderate Hepatic Impairment (Group 2)

    All participants will receive a single dose of MK-8527 on Day 1.

    Drug: MK-8527

  • Experimental
    Healthy (Group 3)

    All participants will receive a single dose of MK-8527 on Day 1.

    Drug: MK-8527

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve from 0 to the time of the last quantifiable sample (AUC0-last) of MK-8527

    Plasma samples will be collected at pre-specified timepoints to determine the AUC0-last of MK-8527.

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  2. Area under the concentration versus time curve from 0 to infinity (AUC0-inf) of MK-8527

    Plasma samples will be collected at pre-specified timepoints to determine the AUC0-inf of MK-8527.

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  3. Maximum Observed Concentration (Cmax) of MK-8527

    Plasma samples will be collected at pre-specified timepoints to determine the Cmax of MK-8527.

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  4. Time to Maximum Concentration (Tmax) of MK-8527

    Plasma samples will be collected at pre-specified timepoints to determine the Tmax of MK-8527.

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  5. Apparent Terminal Half-life (t1/2) of MK-8527

    Plasma samples will be collected at pre-specified timepoints to determine the t1/2 of MK-8527.

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  6. Apparent Clearance (CL/F) of MK-8527

    Plasma samples will be collected at pre-specified timepoints to determine the CL/F of MK-8527.

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  7. Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527

    Plasma samples will be collected at pre-specified timepoints to determine the Vz/F of MK-8527.

    Time frame: Predose and at designated timepoints up to 168 hours post dose

Secondary outcomes

  1. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: Up to approximately 29 days

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: Up to approximately 29 days

  3. AUC0-inf of MK-8527-triphosphate (TP) in peripheral blood mononuclear cell (PBMCs)

    Blood samples will be collected to determine the AUC0-inf of MK-8527-TP.

    Time frame: Predose and at designated timepoints up to 672 hours post dose

  4. Area under the concentration versus time curve from 0 to 672 hours after dosing (AUC0-672hrs) of MK-8527-TP in PBMCs

    Blood samples will be collected to determine the AUC0-672 of MK-8527-TP.

    Time frame: At designated timepoints pre dose and up to approximately 672 hours post dose

  5. Cmax of MK-8527-TP in PBMCs

    Blood samples will be collected to determine the Cmax of MK-8527-TP.

    Time frame: Predose and at designated timepoints up to 672 hours post dose

  6. Concentration at 672 Hours (C672) of MK-8527-TP in PBMCs

    Blood samples will be collected to determine the C672 of MK-8527-TP.

    Time frame: Predose and at designated timepoints up to 672 hours post dose

  7. Tmax of MK-8527-TP in PBMCs

    Blood samples will be collected to determine the Tmax of MK-8527-TP.

    Time frame: Predose and at designated timepoints up to 672 hours post dose

  8. T1/2 of MK-8527-TP in PBMCs

    Blood samples will be collected to determine the Tmax of MK-8527-TP.

    Time frame: Predose and at designated timepoints up to 672 hours post dose

07

Study locations

1 site
  • Arizona Clinical Trials ( Site 0001)
    Chandler, Arizona 85225, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Feb 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Sep 19, 2025
Primary completionActual
Feb 13, 2026
CompletionActual
Feb 13, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07025551
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Sep 19, 2025
Primary completion
Feb 13, 2026
Completion
Feb 13, 2026
Last update
Feb 27, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion